Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature

BACKGROUND: Landiolol hydrochloride, a highly cardio-selective beta-1 blocker with an ultra-short-acting half-life of 4 minutes, was originally approved by Japan for treatment of intraoperative tachyarrhythmias. This review aims to provide an integrated overview of the current state of knowledge of...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuishi, Yujiro, Mathis, Bryan J, Shimojo, Nobutake, Kawano, Satoru, Inoue, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138627/
https://www.ncbi.nlm.nih.gov/pubmed/32308404
http://dx.doi.org/10.2147/VHRM.S210561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138627/
https://www.ncbi.nlm.nih.gov/pubmed/32308404
http://dx.doi.org/10.2147/VHRM.S210561

Ejemplares similares